多囊卵巢综合征女性妊娠不同阶段抗苗勒管激素浓度的变化趋势
本研究为观察性研究,纳入52例多囊卵巢综合征(PCOS)女性和51例对照,纵向测定孕前及全孕期各 trimester 的抗苗勒管激素(AMH)水平。结果显示两组AMH从孕前至各孕期均显著下降(均P<0.05);校正母亲年龄、孕龄和BMI后,PCOS组孕前AMH为对照组的1.89倍(95%CI 1.46-2.44),孕早期为1.61倍(95%CI 1.22-2.13),孕中、晚期差异未达统计学显著。
要点
- PCOS组与对照组AMH从孕前至各孕期均显著下降(均P<0.05)。
- PCOS组孕前AMH中位数7.66 ng/ml,对照组2.67 ng/ml。
- 孕中期和孕晚期两组AMH差异未达统计学显著。
核心结论
- 这些发现表明存在与妊娠相关的AMH下降,且独立于孕前升高的AMH水平。
研究设计与样本
- 观察性研究,包含横断面和纵向数据分析。
- 采用Beckman Coulter AMH Gen II Assay纵向测定52例PCOS女性和51例对照孕前及全孕期各trimester的AMH水平。
- 采用Wilcoxon符号秩检验比较相邻孕期AMH水平差异,采用校正BMI、孕龄和母亲年龄的线性回归模型比较PCOS组与对照组AMH水平。
主要发现
- PCOS组和健康对照组AMH水平从孕前至各孕期均显著下降(均P<0.05)。
- 校正母亲年龄、孕龄和母亲BMI后,PCOS组孕前AMH为对照组的1.89倍(95%CI 1.46至2.44;P<0.0001),中位数7.66 ng/ml vs 2.67 ng/ml。
- 孕早期PCOS组AMH为对照组的1.61倍(95%CI 1.22至2.13;P=0.001),中位数5.33 ng/ml vs 2.48 ng/ml。
- 孕中期PCOS组AMH为对照组的1.68倍(95%CI 0.94至3.01),中位数5.50 ng/ml vs 2.20 ng/ml,差异未达统计学显著。
- 孕晚期PCOS组AMH为对照组的1.45倍(95%CI 1.01至2.07),中位数1.36 ng/ml vs 1.06 ng/ml,差异未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What are the trends in anti-Müllerian hormone (AMH) concentrations from pre-conception to the third trimester of pregnancy in women with polycystic ovary syndrome (PCOS)? DESIGN: Observational study including cross-sectional and longitudinal data analysis. The Beckman Coulter AMH Gen II Assay was used to determine AMH levels longitudinally before pregnancy from 52 women with PCOS and 51 controls during all trimesters. Differences in AMH levels across successive stages of pregnancy were examined with the Wilcoxon signed-rank test for paired values. Linear regression models, adjusted for body-mass index (BMI), gestational and maternal age were used to compare AMH levels of PCOS and controls. RESULTS: AMH levels decreased significantly (all P < 0.05) from pre-pregnancy level throughout each trimester in women with PCOS and healthy controls. After adjusting for maternal age, gestational age and maternal BMI, AMH levels before pregnancy were 1.89 (95% CI 1.46 to 2.44; P < 0.0001) times higher among women with PCOS compared with controls (median 7.66 versus 2.67 ng/ml). During the first trimester, AMH levels were 1.61 (95% CI 1.22 to 2.13; P = 0.001) times higher among women with PCOS compared with controls (median 5.33 versus 2.48 ng/ml). Differences in AMH levels between women with PCOS and controls in the second trimester (1.68 times higher; 95% CI 0.94 to 3.01; median: 5.50 versus 2.20 ng/ml) and the third trimester (1.45 times higher; 95% CI 1.01 to 2.07; median: 1.36 versus 1.06 ng/ml) were not statistically significant. CONCLUSION: These findings indicate a pregnancy-associated AMH-decline independent of pre-pregnancy elevated AMH levels.
引用
- Köninger A, Kampmeier A, Schmidt B, et al. Trends in anti-Müllerian hormone concentrations across different stages of pregnancy in women with polycystic ovary syndrome. Reprod Biomed Online. 2018. PMID: 30146442. doi:10.1016/j.rbmo.2018.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。